Mariadelina Simeoni1, Ramona Nicotera1, Elena Pelagi1, Emanuela Libri1, Nicolino Comi1, Giorgio Fuiano1.
Abstract
INTRODUCTION: The early suspension of Altitude trial in recent years has induced most nephrologists and cardiologists to abandon Aliskiren use. Consequently, the potential usefulness of the direct renin inhibition in IgA glomerulonephritis remained an under-investigated therapeutic option. CASE REPORT: We report the case of a 53 years old IgA GMN patient unresponsive to all conventional anti-angiotensin-2 agents, steroids and immunosuppressants, in which the administration of Aliskiren permitted to achieve and maintain a complete proteinuria remission in the absence of any adverse event.
CONCLUSION: Aliskiren might represent a valid and safe therapeutic option in IgA GMN, although further investigations would be needed to confirm this conclusion. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
INTRODUCTION: The early suspension of Altitude trial in recent years has induced most nephrologists and cardiologists to abandon Aliskiren use. Consequently, the potential usefulness of the direct renin inhibition in IgA glomerulonephritis remained an under-investigated therapeutic option. CASE REPORT: We report the case of a 53 years old IgA GMN patient unresponsive to all conventional anti-angiotensin-2 agents, steroids and immunosuppressants, in which the administration of Aliskiren permitted to achieve and maintain a complete proteinuria remission in the absence of any adverse event.
CONCLUSION: Aliskiren might represent a valid and safe therapeutic option in IgA GMN, although further investigations would be needed to confirm this conclusion. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Entities:
Keywords:
Aliskiren; Chronic Kidney Disease (CKD).; IgA GMN; case report; conventional therapies; proteinuria
Mesh：
Substances：
Year: 2019
PMID： 30047335 DOI： 10.2174/1574887113666180726103648
Source DB: PubMed Journal: Rev Recent Clin Trials ISSN： 1574-8871